To compare the therapeutic efficacy of ceftriaxone given once daily for 5 days and chloramphenicol given four times daily for 14 days, a controlled trial was carried out with 59 patients who were culture positive for SalmoneUla typhi. Ceftriaxone was given to 28 patients in once-daily intravenous doses of 75 mg/kg of body weight to children and 4 g to adults for 5 days; chloramphenicol was given to 31 patients at a dosage of 60 mg/kg/day until defervescence and then at 40 mg/kg/day to complete 14 days of treatment. All Salmonela isolates were susceptible to both antibiotics. Clinical cures (defervescence without complications, no relapse, and no need for further treatment) occurred in 79% of the patients treated with ceftriaxone and 90% of those treated with chloramphenicol (P = 0.37). On the third day of treatment, blood cultures were positive for S. typhi for 60%o of the patients in the chloramphenicol group and 0%o of the ceftriaxone group (P = 0.001).
significantly lower for the chloramphenicol group than those for the ceftriaxone group (P = 0.01 and P = 0.02, respectively). These results indicate that the effects of therapy with ceftriaxone for typhoid fever differed from those of chloramphenicol therapy in that blood cultures became negative earlier, prolonged fever persisted in some patients, and bone marrow suppression was reduced. We conclude that a short, 5-day course of ceftriaxone is a useful alternative to conventional 14-day chloramphenicol therapy in the treatment of typhoid fever.
Chloramphenicol has been the treatment of choice for typhoid fever for nearly 40 years, particularly in developing countries, where the cost of treatment is of considerable importance. However, newer antibiotics with good in vivo activity against Salmonella typhi are needed because of the alarming spread of R-factor-mediated chloramphenicol-resistant S. typhi throughout the world (3, 4, 11, 23) . Recently, ceftriaxone has emerged as a satisfactory alternative to chloramphenicol (1, 2, 5, 8, 10, 12, 13, 21, 22) .
Ceftriaxone has good broad-spectrum activity against gram-positive and gram-negative bacteria, including S. typhi (15) . It has a long half-life in serum (ranging from 6.0 to 8.6 h), making it suitable for a once-daily dose regimen (16, 20) . Randomized trials comparing chloramphenicol to ceftriaxone given once daily for 7 days for typhoid fever in Bangladesh (8) showed an efficacy of ceftriaxone comparable to that of chloramphenicol. The need for less expensive, shorter regimens prompted us to evaluate further the efficacy of ceftriaxone for treating typhoid fever in both children and adults; use of ceftriaxone would reduce the duration of therapy to 5 4 2 included one patient who had a relapse after discharge, two who developed pneumonia in the hospital, one who developed a urinary tract infection, and two who remained febrile for more than 14 days after the start of treatment without an apparent cause for the fever and were given chloramphenicol. The ages of the six patients not cured with ceftriaxone were 6, 15, 16 (two patients), 20, and 30 years, indicating that clinical failure occurred in children and adults alike. The three patients in the chloramphenicol group who were not cured included one patient who had a relapse and two who had urinary tract infections. The rates of defervescence in the ceftriaxone and chloramphenicol groups were similar (50 versus 51%) in the first week after the start of treatment (Fig. 1) , but during the second week, on days 9 through 13, nine patients in the ceftriaxone group and six patients in the chloramphenicol group remained febrile; however, this difference was not statistically significant (P = 0.4). Despite the persistence of fever in patients treated with ceftriaxone, most of the patients experienced clinical improvement. The mean maximal temperature on the 10th day after the start of treatment in 15 patients who were still febrile was 38.4°C, compared Bacteriologic response to treatment. At the end of the 14-day observation period, blood cultures were negative for all patients. Blood cultures obtained on the third day of treatment, however, were still positive for S. typhi for 20 patients receiving chloramphenicol, whereas they were negative for all patients receiving ceftriaxone (P = 0.001) ( Table  2) . Stool cultures were positive after the start of treatment for only two patients in the ceftriaxone group. Seventeen patients (61%) in the ceftriaxone group and 23 patients (74%) in the chloramphenicol group returned for follow-up visits a week or more after discharge. Two patients (one in each treatment group) with clinical relapses detected 1 to 2 weeks after discharge had stool cultures positive for S. typhi. One patient in the chloramphenicol group had a positive stool culture 1 week after discharge but had no fever.
Hematologic effects of treatment. Patients who received chloramphenicol showed a significantly lower median hematocrit (30.5%) on day 14 after the start of treatment than the patients treated with ceftriaxone (hematocrit, 34.5%) (P = 0.01) ( Table 3 ). The median leukocyte count on day 14 was also lower for patients treated with chloramphenicol (P = 0.02), but the median platelet counts did not differ significantly between the treatment groups (P = 0.17).
The median duration of diarrhea after therapy was similar (3.0 days) in both groups. Patients treated with ceftriaxone had a median volume of stool passed on day 1 of 12.0 ml/kg of body weight, compared with 17.2 ml/kg for those treated with chloramphenicol, which was not significantly different (P = 0.7). Similarly, the cumulative stool volumes on day 3 were 38.8 versus 55 ml/kg for the ceftriaxone and chloramphenicol groups, respectively (P = 0.3). Microscopic examination of stool samples from the 59 patients revealed ova of Ascaris lumbricoides, alone or in association with ova of Trichuris trichiura and Ankylostoma duodenale, in 50 and 51% of patients treated with ceftriaxone and chloramphenicol, respectively. No other side effects in patients of either treatment group were noted, except that one patient in the Patients treated with ceftriaxone, on the other hand, were more likely to remain febrile for a week or more after the start of treatment than patients treated with chloramphenicol. The proportion of patients having prolonged fever (lasting .10 days) was 32% for patients treated with ceftriaxone, compared with 23% reported by Islam et al. (8) for patients with typhoid fever who were treated with ceftriaxone for 7 days. The reasons for prolonged fever in some cases were superinfections leading to pneumonia or urinary tract infection. In other cases, the causes of prolonged fever could not be determined. It is unlikely that inadequate levels of antibiotic in the blood occurred during treatment, because concentrations of ceftriaxone in blood were measured by Islam et al. (8) in patients with typhoid fever 24 h after intravenous doses and were well above the MICs for Salmonella spp. (5) . Most of the patients, despite the persistence of fever, improved clinically, and their maximal daily temperatures declined.
One disadvantage of giving chloramphenicol for the treatment of typhoid is that it causes suppression of the bone marrow. In this study, patients treated with chloramphenicol showed significantly lower hematocrits at the end of treatment than patients treated with ceftriaxone. The median leukocyte count was also significantly lower in patients treated with chloramphenicol. These findings were similar to those of a previous study by Islam et al. (8) , which showed lower mean counts of leukocytes and platelets after treatment of typhoid fever.
Another disadvantage of chloramphenicol treatment of typhoid fever is a high rate of relapse after treatment. In a recent outbreak of typhoid fever in Israel, 36% of the patients treated with chloramphenicol experienced relapses (7) . Only one patient (3%) in each treatment group of our study was observed to have had a relapse, but this could be an underestimation of the true relapse rate, because the rate of return visits following hospital discharge was not 100%. In the study of Robertson et al. in Egypt (17) , relapses occurred in 8% of typhoid patients treated with chloramphenicol versus 0% of patients treated with ampicillin, indicating that perhaps beta-lactam antibiotics are more effective in preventing relapses. Other studies using beta-lactams in typhoid fever treatment that show trends of lower relapse rates were reported by Saunders (19) for ampicillin, Morelli et al. (14) for cefoperazone, and Farid et al. (6) for aztreonam.
Ceftriaxone for treating typhoid fever will be useful for patients in whom a shorter course of injectable-drug therapy is preferable. Additionally, ceftriaxone will have a role in treating infections resistant to other antibiotics (3, 4, 9, 11, 18, 23) .
